Study of MGC026 for advanced solid tumors
Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new drug called MGC026 that targets a protein called B7-H3 on cancer cells, aiming to shrink or slow different advanced solid tumors. It is an early-phase study to find the right dose and check safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and in generally good health (based on lab tests and daily activity level).
- You must have a type of advanced solid tumor that can't be removed by surgery or has spread, from a list including head and neck, lung, bladder, breast, prostate, colorectal, and others.
- You must have a tumor sample available (from a past biopsy) or be able to safely get a new biopsy.
- You must not have had certain prior cancer treatments within a specific time window, or any prior treatment with B7-H3 or topoisomerase-targeting drugs.
- You must not have active infections or major medical conditions affecting your heart, lungs, or stomach, or a history of untreated brain metastases.
- Women must not be pregnant or breastfeeding, and all participants must use effective birth control during and for 7 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called MRG007 for people with advanced solid tumors that haven't responded to other treatments. The drug targets a protein called CDH17 on cancer cells; you need a tumor sample to check for it.
This trial tests a new study drug, GV20-0251, for people with advanced solid tumors that no longer respond to standard therapies. It aims to see if the drug can shrink tumors or slow their growth.
This trial tests a new investigational drug called MGC030 for people with advanced solid tumors, including bladder, colorectal, stomach, esophageal, or pancreatic cancer. The goal is to see if the drug is safe and can help shrink or control the cancer when standard treatments have stopped working.
This early-phase trial tests how well a new drug (BMS-986340) works alone and combined with other treatments in people with advanced solid tumors that have progressed despite standard care. It also studies tumor samples to look for biomarkers that may predict who benefits.
This trial tests a new drug called GV20-0251 combined with an immunotherapy (anti-PD-1) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests an investigational drug (BMS-986463) in people with advanced solid tumors. It aims to find a safe dose and see if it helps shrink or control the cancer. You must be well enough to do daily activities and have a tumor that can be biopsied before treatment starts.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.